Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

TSX rises as energy stocks gain on COVID-19 vaccine progress

11/23/2020 | 10:04am EST

Nov 23 (Reuters) - The energy sector drove Canada's main stock index higher on Monday, as more signs of progress in developing a COVID-19 vaccine bolstered hopes of an economic revival and lifted oil prices.

* The energy sector climbed 2.1% as U.S. crude prices were up 1.0% a barrel while Brent crude added 1.4%.

* At 9:34 a.m. ET (14:34 GMT), the Toronto Stock Exchange's S&P/TSX composite index was up 40.82 points, or 0.24%, at 17,059.92.

* AstraZeneca said its COVID-19 vaccine could be around 90% effective, while a top official of U.S. government's vaccine development effort said the country's health regulator is likely to approve the distribution of Pfizer and BioNTech's shot in mid-December.

* The largest percentage gainers on the TSX were oil producers Enerplus Corp, which jumped 4.3%, and Whitecap Resources Inc, which rose 4.1%.

* Canada's wholesale trade in October likely increased by 0.9%, after rising 0.9% in September, Statscan said in a flash estimate.

* The financials sector gained 0.7%. The industrials sector rose 0.2%.

* The materials sector, which includes precious and base metals miners and fertilizer companies, lost 0.8%.

* On the TSX, 143 issues were higher, while 71 issues declined for a 2.01-to-1 ratio favoring gainers, with 19.70 million shares traded.

* Miner Pan American Silver Corp fell 2.5%, the most on the TSX, and the second-biggest decliner was New Gold Inc, down 2.5%.

* The most heavily traded shares by volume were Manulife Financial Corp, Sun Life Financial Inc, and Bombardier Inc.

* The TSX posted three new 52-week highs and no new lows.

* Across all Canadian issues there were 45 new 52-week highs and two new lows, with total volume of 31.80 million shares. (Reporting by Amal S in Bengaluru; Editing by Aditya Soni)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.25% 7773 Delayed Quote.6.21%
ENERPLUS CORPORATION 0.96% 4.19 Delayed Quote.5.28%
LONDON BRENT OIL -0.18% 55.43 Delayed Quote.7.08%
PAN AMERICAN SILVER CORP. -5.06% 36 Delayed Quote.-18.00%
PFIZER INC. -2.87% 36.24 Delayed Quote.-1.55%
S&P/TSX COMPOSITE INDEX -2.00% 17424.43 Delayed Quote.2.71%
SILVER -0.41% 25.048 Delayed Quote.-3.41%
SUN LIFE FINANCIAL INC. -1.91% 59.01 Delayed Quote.4.26%
WHITECAP RESOURCES INC. 0.00% 4.74 Delayed Quote.-2.47%
WTI 0.20% 52.489 Delayed Quote.8.49%
All news about ASTRAZENECA PLC
01/27ASTRAZENECA : COVID-19 Vaccine Production Unaffected After Suspicious Package 'M..
01/27ASTRAZENECA : EU Asks AstraZeneca to Source COVID-19 Doses from British Plants
01/27ASTRAZENECA : COVID-19 Vaccine Wins Emergency Use Approval In Philippines
01/27ASTRAZENECA ALERT : Bragar Eagel & Squire, P.C. Announces That a Class Action La..
01/27PFIZER : Tensions rise as AstraZeneca, EU spar over vaccine delays
01/27GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Inv..
01/27ASTRAZENECA : Morocco to start vaccinations on Thursday, palace says
01/27EU Clashes With AstraZeneca Over Covid-19 Vaccine Shortfall
01/27EU health official blasts slow vaccine delivery, and is consulting with Canad..
01/27Do we need to sanction each other? German minister asks after Blinken call
More news
Financials (USD)
Sales 2020 26 378 M - -
Net income 2020 2 951 M - -
Net Debt 2020 13 468 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 140 B -
EV / Sales 2020 5,80x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 127,03 $
Last Close Price 106,32 $
Spread / Highest target 47,8%
Spread / Average Target 19,5%
Spread / Lowest Target -15,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035